Clinical Trial Update: Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 safety study of SGX523, a MET inhibitor, in patients with advanced solid tumors; the study was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• SGX523

Snippet

Sponsor: SGX Pharmaceuticals, Inc. | Conditions: Advanced Cancer | Phase 1 | Status: TERMINATED